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Background: The role of histology in the targeted management of nonsmall cell lung cancer 
(NSCLC) has garnered renewed attention in recent years. We provide contemporary population-
based estimates of survival and an assessment of important prognostic factors in stage IV NSCLC 
by major histologic subtype.
Methods: Using data from the Surveillance, Epidemiology and End Results (SEER) Program, 
we stratified 51,749 incident stage IV NSCLC patients (1988–2003 with follow-up through 2006) 
by major histologic subtype. We used Kaplan–Meier and Cox proportional hazards methods 
to describe overall survival and the prognostic influence of select patient, tumor, and treatment 
characteristics for each histologic subgroup.
Results: Survival was highest in patients with bronchioloalveolar adenocarcinoma (1-year 
  survival: 29.1%) and lowest in those with large cell tumors (1-year survival: 12.8%). Diagnosis in 
later years, female gender, younger age, either Asian/Pacific Islander or Hispanic race/ethnicity, 
lower tumor grade, and surgery or beam radiation as part of first-line treatment were generally 
independently associated with a decreased risk of death, but the prognostic significance of some 
of these factors (age, ethnicity, tumor grade) varied according to histologic subtype.
Conclusion: Findings demonstrate a poor prognosis across histologic subtypes in stage IV 
NSCLC patients but highlight differences in both absolute survival and the relative importance 
of select prognostic factors by histologic subclassification. More research using other sources of 
population-based data could help clarify the role of histology in the presentation, management, 
and prognosis of late-stage NSCLC.
Keywords: epidemiology, nonsmall cell lung cancer, histology, survival
Introduction
Lung cancer is the second most commonly diagnosed cancer in the US and accounts 
for the greatest number of cancer-related deaths in both men and women. In 2010, an 
estimated 222,520 people were diagnosed with lung cancer and nearly 157,300 died 
from this disease.1 Representing approximately 85% of lung cancer cases, nonsmall 
cell lung cancer (NSCLC) presents as metastatic disease in over half of all cases and 
is associated with a poor prognosis.2 The 5-year relative survival rate is just 17% for 
patients diagnosed with NSCLC and less than 4% in the subset presenting with distant 
metastases.2
Several studies have highlighted potentially important prognostic indicators of 
NSCLC survivorship but with somewhat conflicting conclusions, particularly with respect Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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to demographic factors.3–9 Discordance in past research may 
partly be explained by relatively small study samples, narrow 
treatment inclusion criteria (eg, surgically treated patients), 
varying disease inclusion criteria with respect to tumor histol-
ogy and stage, and limited geographic or population coverage. 
To our knowledge, no current or large-scale investigation 
has reported the relative significance of prognostic factors 
by NSCLC histologic subtype. In recent years, there has 
been marked progress in elucidating the molecular origins of 
NSCLC, better classifying histologic subtypes, and develop-
ing targeted therapies, prompting an increased understanding 
of NSCLC patients by histology.10–13 We undertook this study 
to describe the distribution of patient, tumor, and treatment 
characteristics and their influence on survival, overall and by 
histologic subtype, for patients newly diagnosed with stage IV 
NSCLC using data from the Surveillance, Epidemiology and 
End Results (SEER) Program.
Materials and methods
study population
We conducted this retrospective cohort study using data 
collected by the National Cancer Institute’s SEER Program, 
an authoritative, population-based source of information on 
cancer incidence and survival in the US.14 SEER routinely 
gathers data on patient demographics, primary tumor site, 
tumor morphology and stage at diagnosis, first course of 
treatment, and follow-up for vital status. We limited our 
study to data collected by the first nine registries supported 
by SEER (Connecticut, Iowa, New Mexico, Utah, Hawaii, 
Atlanta, Detroit, San Francisco-Oakland, and Seattle-Puget 
Sound), representing nearly 10% of the US population, to 
maximize the time period covered and allow for an assess-
ment of epidemiologic trends over time.
We selected patients with a first and only primary 
diagnosis of stage IV cancer of the lung and bronchus 
(C34.0–C34.9, International Classification of Diseases for 
Oncology, 3rd Edition [ICD-O-3])15 between January 1, 1988 
and   December 31, 2003. This case ascertainment period was 
chosen because these are the years for which SEER consis-
tently coded stage of disease according to the third edition 
of the American Joint Committee on Cancer (AJCC) staging 
criteria. We restricted our analyses to patients diagnosed 
with nonsmall cell tumors and categorized them according 
to ICD-O-3 histologic subtype: squamous and transitional 
cell (8051–8052, 8070–8084, 8120–8131), adenocarcinoma 
(bronchioloalveolar adenocarcinoma [BAC]: 8250–8255 
and non-BAC: 8050, 8140–8149, 8160–8162, 8190–8221, 
8256–8263, 8270–8280, 8290–8337, 8350–8390, 8400–8560, 
8570–8576, 8940–8941), large cell (8011–8015), and 
“other” (8010, 8020–8022, 8030–8040, 8046, 8090–8110, 
8150–8156, 8170–8175, 8180, 8230–8231, 8240–8249, 
8340–8347, 8561–8562, 8580–8671). We excluded patients 
who were identified by death certificate or autopsy only and 
those who died within 30 days after diagnosis (representing 
less than 8% of the otherwise eligible study population), 
because SEER reports survival time in months. Because this 
represents a publicly available dataset in which individual 
patient identification is not possible, informed consent by 
participating patients was not necessary.
statistical analysis
We examined the distribution of incident stage IV NSCLC 
patients overall and by NSCLC histologic subtype according 
to time period of diagnosis and patient, tumor, and treatment 
characteristics. Data on vital status were available through 
December 31, 2006. The Kaplan–Meier16 method was used 
to describe overall 1- and 5-year survival for all stage IV 
NSCLC patients and for each histologic group by variables 
of interest. To ensure at least 5 years of patient follow-up for 
these estimates of survival, we limited these analyses to those 
diagnosed through December 31, 2001. Log-rank tests were 
used to assess the differences between select survival curves. 
Cox proportional hazards (PH) modeling17 was used to deter-
mine the independent influence of prognostic factors on the 
risk of death (from all causes) in stage IV NSCLC patients 
separately for each histologic subtype. Patients were followed 
from the date of diagnosis (1988–2003) to the date of death 
and were censored at the date they were last known to be 
alive (if lost to follow-up) or December 31, 2006, whichever 
came first. Log(-log) survival plots against time confirmed 
that proportionality assumptions were met. A two-sided 
P value ,0.05 was considered statistically significant. The 
statistical software Stata/SE 9.1 for Windows (StataCorp LP, 
College Station, TX) was used for all analyses.
Results
Demographics by histologic subtype
A total of 51,749 patients diagnosed with stage IV NSCLC 
during 1988–2003 were included for study (Table 1). Median 
follow-up time was 4 months (range 1–225). Men predomi-
nated in all histologic subtypes (ranging from 56% in non-
BAC adenocarcinoma to 69% in squamous) except in BAC 
tumors, where women represented 52% of the cases. Mean 
age at diagnosis ranged from 64.2 years in both non-BAC 
adenocarcinoma and large cell subtypes to 67.1 years in 
“other” NSCLC tumors. Although White patients accounted Clinical Epidemiology 2011:3
Table 1 Distribution of stage iV nonsmall cell lung cancer (nsCLC) cases according to select variables by histologic subtype based on 
data from the nine surveillance, Epidemiology and End results Program registries
Characteristica NSCLC histologic subtype Overall 
n = 51,749   
(100%)
Squamous 
n = 9370 
(18%)
Adenocarcinoma Large cell 
n = 4689 
(9%)
Other 
n = 15,020 
(29%)
Non-BAC 
n = 21,869 
(42%)
BAC 
n = 801 
(2%)
Period of diagnosis
  1988–1992 35% 29% 24% 40% 22% 29%
  1993–1997 29% 31% 30% 31% 27% 29%
  1998–2003 36% 41% 47% 29% 51% 42%
gender
  Male 69% 56% 48% 63% 59% 60%
  Female 31% 44% 52% 37% 41% 40%
Age at diagnosis
  ,45 years 2% 5% 4% 4% 3% 4%
  45–54 years 10% 15% 12% 15% 12% 13%
  55–64 years 25% 28% 24% 30% 24% 26%
  65–74 years 38% 32% 31% 32% 33% 33%
  75–84 years 21% 17% 24% 17% 23% 20%
  85+ years 3% 2% 5% 2% 5% 3%
Mean (sD), years 66.9 (10.3) 64.2 (11.4) 66.8 (11.9) 64.2 (11.0) 67.1 (11.6) 65.6 (11.3)
Ethnicity/race
  White 77% 79% 75% 79% 78% 78%
  Black 14% 11% 9% 13% 12% 12%
  American indian/Alaskan native ,1% ,1% ,1% ,1% ,1% ,1%
  Asian/Pacific Islander 5% 7% 12% 4% 6% 6%
  spanish/hispanic/Latino 3% 3% 4% 3% 3% 3%
Tumor grade at diagnosis
  Well differentiated 2% 3% 21% ,1% ,1% 2%
  Moderately differentiated 18% 11% 11% ,1% 1% 8%
  Poorly differentiated 39% 35% 7% 24% 29% 33%
  Undifferentiated 2% 2% 1% 39% 7% 7%
  Unknown 40% 49% 60% 37% 64% 51%
Cancer-directed surgery
  none 90% 86% 81% 89% 92% 89%
  Lobectomy/bilobectomy 2% 2% 6% 2% 1% 2%
  Pneumonectomy 1% ,1% 1% ,1% ,1% ,1%
  Other cancer-directed surgeryb 7% 11% 12% 9% 7% 9%
radiation
  none 36% 41% 69% 36% 48% 42%
  External beam radiation 64% 59% 31% 64% 51% 57%
  Other radiationc ,1% 1% 0% 1% 1% 1%
Median follow-up (range) 4 months 
(1–225)
5 months 
(1–215)
6 months 
(1–198)
4 months 
(1–200)
4 months 
(1–219)
4 months 
(1–225)
Notes: aColumn percentages may not add up to 100 because of rounding; bOther cancer-directed surgery includes local surgical tumor destruction and excision/resection 
of less than one lobe; cOther radiation includes radioactive implants only, radioisotopes only, and radiation not otherwise specified.
Abbreviations: BAC, bronchioloalveolar adenocarcinoma; sD, standard deviation.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
141
survival by histologic subtype in stage iV nsCLC
for at least 75% of cases in every histologic subtype, a higher 
proportion of BAC patients were Asian/Pacific Islanders 
(APIs) compared with the other histologic groups.
Tumor grade and treatment  
by histologic subtype
The distribution of stage IV NSCLC tumors by grade var-
ied considerably according to histologic subtype (Table 1). 
The highest proportion of well-differentiated tumors was 
observed in BAC (21%), whereas the percentage of undif-
ferentiated tumors was greatest in the large cell group 
(39%). Unknown tumor grade ranged from 37% in large cell 
tumors to 64% in “other” NSCLC tumors.   Overwhelmingly, 
the majority (89%) of stage IV NSCLC patients did not 
undergo site-directed surgery as part of first-line treat-
ment, but over half (57%) received external beam radiation Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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(Table 1). Surgery was most common in those diagnosed with 
  adenocarcinomas, particularly for BAC patients: 6% under-
went a lobectomy/bilobectomy, 1% had a pneumonectomy, 
and 12% had local surgical tumor destruction or excision. 
Conversely, fewer patients with BAC tumors received beam 
radiation as part their initial therapy (31%) compared with 
the other histologic groups, and beam radiation treatment 
was highest in those with squamous or large cell tumors 
(64% in each).
Univariate analysis of survival  
by histologic subtype
By December 31, 2006, 51,081 patients (99% of the study 
sample) had died from all causes and 45,347 (88%) had died 
from lung cancer specifically. Table 2 displays unadjusted 
1- and 5-year survival rates for stage IV NSCLC patients as 
a whole and by histologic subtype according to select vari-
ables. Survival was highest for patients with BAC tumors 
(1-year survival: 29.1% [95% confidence interval (CI): 25.7, 
32.6]; 5-year survival: 4.4% [95% CI: 3.0, 6.1]) and lowest 
in those diagnosed with large cell tumors (1-year survival: 
12.8% [95% CI: 11.8, 13.8]; 5-year survival: 1.1% [95% 
CI: 0.8, 1.4]). Median survival for all stage IV NSCLC 
patients combined was 4 months (95% CI: 4, 4), with a 
range of 1–225 months. Survival significantly differed by 
histologic subgroup, primarily driven by the higher survival 
observed in patients with BAC (median survival: 6 months 
[95% CI: 6, 7]) (Figure 1).
Across histologic groups, survival in stage IV NSCLC 
patients tended to improve for those diagnosed in later years 
and was more favorable in females than in males (Table 2). 
Survival for stage IV NSCLC patients generally worsened 
with increasing age at diagnosis and varied by race/  ethnicity, 
with survival estimates typically highest in Hispanic and 
API patients. Survival worsened with increasing tumor 
grade at diagnosis and was better for those who underwent 
site-directed surgery as part of first-line treatment than for 
those who did not.
Multivariate analysis of survival  
by histologic subtype
We performed Cox PH analysis on stage IV NSCLC patients 
separately for each histologic subtype (Table 3). Mirroring 
univariate trends in survival, results indicated that across 
histologic subtypes, diagnosis in later years, female   gender, 
younger age at diagnosis (,65 years), either API or   Hispanic 
race/ethnicity (versus White), lower tumor grade at diag-
nosis, and cancer-directed surgery or beam radiation as 
part of first-line treatment were generally all independently 
associated with a decreased risk of death (all-cause). The 
nature and strength of these associations did not change 
when surgery and radiation were excluded from the models 
(data not shown).
The prognostic significance of some factors varied 
according to histologic subtype. A clear pattern of disparate 
outcomes by age at diagnosis was not apparent in patients 
with squamous cell or BAC tumors. With respect to race/
ethnicity, compared with Whites, the negative prognostic 
influence of Black race/ethnicity was not observed in patients 
diagnosed with “other” NSCLC tumors (adjusted hazard 
ratio [aHR]: 0.98 [95% CI: 0.93–1.03]), and the increased 
risk of death associated with an American Indian/Alaskan 
Native background was particularly pronounced in those 
with squamous (aHR: 1.58 [95% CI: 1.12–2.22]) or BAC 
(aHR: 3.62 [95% CI: 0.89–14.65]) tumors. Further, the 
favorable prognostic effect of Hispanic race/ethnicity was not 
demonstrated in squamous or large cell subgroups. Although 
survival in stage IV NSCLC tended to improve over time 
across histologic subtypes, this improvement was evident 
early on and was strongest in patients with large cell tumors 
(compared with cases diagnosed in 1988–1992, aHR: 0.93 
[95% CI: 0.87–1.00] for 1993–1997 and aHR: 0.77 [95% 
CI: 0.71–0.83] for 1998–2003). Lastly, although increasing 
tumor grade was generally associated with poorer survival 
in stage IV NSCLC patients, no relationship between tumor 
grade and prognosis was apparent among those diagnosed 
with BAC or large cell tumors.
Discussion
Findings confirm the poor prognosis in patients diagnosed 
with stage IV NSCLC, with a median overall survival time 
of just 4 months and 1- and 5-year survival of less than 16% 
and 2%, respectively. In this large population-based cohort 
of newly diagnosed stage IV NSCLC patients, we observed 
several important trends in survival, some of which differed 
according to histologic subtype.
Consistent with studies demonstrating a gradual improve-
ment in NSCLC survival over the last few decades,18–20 across 
histologic subtypes, we observed a moderate improvement 
in overall survival for patients diagnosed with stage IV 
NSCLC over the study period. For all patients combined, 
there was an absolute increase of 0.7% and 4.1% in 1- and 
5-year survival, respectively, for patients diagnosed in 
1998–2003 versus those diagnosed in 1988–1992. Later years 
of diagnosis were independently associated with a decreased 
risk of death after controlling for important patient, tumor, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Survival time in years
Adeno, Non-BAC (n = 18,898)
Adeno, BAC (n = 666)
Other (n = 12,061)
5-year survival by NSCLC histologic subtype
Squamous cell 
Adenocarcinoma, non-BAC 
Adenocarcinoma, BAC 
Large cell 
Other
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4 months (4, 4) 
4 months (3, 4) 
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Figure 1 Kaplan–Meier survival curves displaying 5-year survival and median survival 
time by histologic subtype for patients diagnosed with stage iV nonsmall cell lung 
cancer (nsCLC).
Abbreviations: Adeno, adenocarcinoma; BAC, bronchioloalveolar adenocarcinoma; 
CI, confidence interval.
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and treatment   characteristics for every histologic subtype. 
Although this may partly be a function of stage migration 
resulting from more advanced imaging techniques over time, 
decreased mortality may also be credited to an increased 
availability of better supportive care measures or systemic 
therapy   regimens. In fact, the timing of improved survival 
coincides with the adoption of platinum-based chemotherapy 
as a standard of care in the stage IV NSCLC setting by the 
American Society of Clinical Oncology,21 and research on 
trends in chemotherapy utilization and outcomes reflect 
this guidance. Using the SEER–Medicare linked database, 
Ramsey et al22 found that between 1994 and 1999, the pro-
portion of stage IIIb and IV NSCLC patients who received 
chemotherapy increased from 21% to 43%, and survival 
outcomes were superior among those receiving at least one 
chemotherapy agent, particularly if that agent was platinum- 
based. Interestingly, although we found that overall survival 
was shortest in patients with large cell tumors, survival 
improvements over time were most pronounced in this 
group. Large cell NSCLC includes large cell neuroendocrine 
carcinomas (LCNECs), and our findings are in concordance 
with research demonstrating that although these patients 
do not experience superior survival, NSCLC tumors with 
neuroendocrine features have a higher objective response 
rate to chemotherapy.21
Gender differences in NSCLC presentation, manage-
ment, and survival have been investigated extensively, 
and the majority of studies demonstrate that compared 
with males, female NSCLC patients are more likely to 
have   adenocarcinoma and be non- or light smokers and 
younger.3–5,8,9,20,23,24 Several reports also indicate a more 
favorable prognosis of NSCLC in women versus men,5,9,23,24 
but this is less clear in the advanced disease setting. Based 
on a retrospective analysis of patients undergoing surgery 
for NSCLC, de Perrot et al5 found that although the pro-
tective effect of female gender was present in early-stage 
NSCLC, it was absent in more advanced disease (stage III 
and IV). Conversely, Visbal et al9 prospectively followed a 
larger cohort of NSCLC patients and noted that men were 
at a significantly increased risk of mortality compared with 
women, especially for those with stage III/IV disease or 
adenocarcinoma. Consistent with this latter study, we found 
that female gender was a significant independent positive 
prognostic factor across histologic subtypes in our cohort 
of stage IV NSCLC patients.
Although many investigations have noted that younger 
NSCLC patients are more likely to be female, have adeno-
carcinoma, receive more aggressive treatment, and have 
biologically aggressive tumors compared with those who are 
elderly, research has not consistently demonstrated a pattern 
of disparate survival outcomes by age group.4,6,7 In our study 
of stage IV NSCLC patients, increasing age was generally 
associated with poorer survival, but there were exceptions to 
this trend according to histologic subtype. For patients with 
squamous cell NSCLC, although the elderly (75+ years) and 
young (,45 years) patients demonstrated poorer and superior 
survival, respectively, risk of death appeared to be comparable 
across the three middle age groups. For patients diagnosed 
with BAC tumors, the prognostic significance of age was 
unclear, although this most likely reflects the relatively small 
number of BAC patients in specific age brackets. Taken as a 
whole, our findings do not support the notion that NSCLC is 
inherently more aggressive or deadlier in younger patients, at 
least not among those who present with stage IV disease.
The prognostic role of race/ethnicity in stage IV NSCLC 
survival varied between histologic subgroups. For most, 
API ethnicity conferred an independent survival advantage. 
Although it is widely recognized that among Asian NSCLC 
patients there is a preponderance of never smokers and that 
never smokers demonstrate superior survival outcomes,25 
recent research suggests that the favorable prognostic effect of 
Asian ethnicity in NSCLC survival is independent of smok-
ing status.18 High levels of epidermal growth factor receptor 
(EGFR) protein have been associated with poorer outcomes 
in NSCLC, and polymorphisms within the EGFR gene that Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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lead to lower EGFR expression are more common in Asians 
compared with in other ethnic groups.18 Also consistent with 
previous research,19,26 we found that Black versus White race/
ethnicity was generally associated with an increased risk of 
death for stage IV NSCLC patients. Additionally, Native 
Americans/Alaskan Natives had reduced survival, particu-
larly among patients with squamous cell or BAC tumors, 
and Hispanics tended to demonstrate relatively favorable 
survival in those with adenocarcinomas or “other” NSCLC 
tumors. Whether these ethnic disparities in stage IV NSCLC 
mortality according to histologic subtype are tied to important 
genetic differences (eg, pharmacogenomic or tumor genetic 
differences associated with anticancer treatment response) 
among races/ethnicities or simply reflect differential access 
to care is an area of active research.27
Although the management of advanced NSCLC remains 
a challenge, our study demonstrates a modest improvement 
in survival over the last few decades, which may partly be 
attributed to the adoption of platinum-based chemotherapy. 
Because histology is increasingly being viewed as an impor-
tant factor in determining appropriate choice of treatment 
regimen,10,11,13 it is concerning that nearly 30% of newly 
diagnosed stage IV NSCLC tumors in our sample were not 
further classified into one of the main histologic subtypes 
(squamous cell, adenocarcinoma, BAC, and large cell). 
Although some of these tumors were of mixed/other NSCLC 
Table 3 Multivariate regression analysis of factors associated with time to death (all-cause) in patients diagnosed with stage iV nonsmall 
cell lung cancer (nsCLC) surviving at least 31 days
Characteristic NSCLC histologic subtype
Squamous 
(n = 9370)
Adenocarcinoma Large cell 
(n = 4689)
Other 
(n = 15,020) Non-BAC 
(n = 21,869)
BAC 
(n = 801) aHRa (95% CI) aHRa (95% CI) aHRa (95% CI)
aHRa (95% CI) aHRa (95% CI)
Period of diagnosis
  1988–1992 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
  1993–1997 1.00 (0.95–1.05) 0.99 (0.96–1.03) 0.95 (0.78–1.16) 0.93b (0.87–1.00) 0.95b (0.91–0.99)
  1998–2003 0.88c (0.84–0.93) 0.89c (0.86–0.92) 0.82b (0.68–0.98) 0.77c (0.71–0.83) 0.86c (0.82–0.89)
gender
  Male 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
  Female 0.90c (0.86–0.94) 0.86c (0.84–0.89) 0.78b (0.68–0.90) 0.91b (0.86–0.97) 0.88c (0.85–0.90)
Age at diagnosis
  ,45 years 0.79b (0.69–0.91) 0.77c (0.72–0.82) 1.00 (0.68–1.46) 0.80b (0.69–0.93) 0.74c (0.67–0.82)
  45–54 years 0.95 (0.89–1.02) 0.83c (0.79–0.86) 0.71b (0.55–0.90) 0.77c (0.70–0.84) 0.78c (0.74–0.83)
  55–64 years 0.98 (0.93–1.03) 0.89c (0.86–0.92) 0.74b (0.61–0.90) 0.88b (0.82–0.95) 0.86c (0.83–0.90)
  65–74 years 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
  75–84 years 1.17c (1.10–1.23) 1.20c (1.15–1.25) 1.02 (0.84–1.23) 1.14b (1.05–1.24) 1.14c (1.09–1.19)
  85+ years 1.28c (1.13–1.46) 1.37c (1.25–1.50) 0.85 (0.60–1.12) 1.26b (1.03–1.55) 1.34c (1.24–1.45)
Ethnicity/race
  White 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
  Black 1.03 (0.97–1.09) 1.05b (1.00–1.10) 1.27 (0.97–1.64) 1.11b (1.02–1.21) 0.98 (0.93–1.03)
    Amer indian/Alaskan 
native
1.58b (1.12–2.22) 1.14 (0.88–1.47) 3.62 (0.89–14.65) 1.05 (0.54–2.01) 1.13 (0.84–1.53)
  Asian/Pacific Islander 0.95 (0.87–1.04) 0.79c (0.74–0.83) 1.09 (0.87–1.37) 0.84b (0.73–0.97) 0.90b (0.84–0.96)
  spanish/hispanic/Latino 1.01 (0.89–1.14) 0.91b (0.84–0.98) 0.81 (0.56–1.17) 1.00 (0.84–1.19) 0.93 (0.85–1.02)
Tumor grade at diagnosis
  Well differentiated 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
  Moderately differentiated 1.08 (0.93–1.25) 1.07 (0.97–1.17) 0.85 (0.64–1.12) 1.35 (0.52–3.50) 1.45 (0.91–2.32)
  Poorly/undifferentiated 1.17b (1.01–1.34) 1.25c (1.14–1.36) 1.05 (0.77–1.42) 0.85 (0.38–1.91) 1.89b (1.25–2.88)
  Unknown 1.13 (0.98–1.30) 1.19c (1.10–1.30) 1.14 (0.96–1.37) 0.87 (0.39–1.95) 1.90b (1.25–2.90)
Cancer-directed surgery
  Yes 0.66c (0.62–0.71) 0.67c (0.64–0.70) 0.46c (0.37–0.56) 0.82c (0.75–0.90) 0.72c (0.67–0.76)
  no 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
External beam radiation
  Yes 0.89c (0.85–0.93) 0.95b (0.93–0.98) 1.04 (0.89–1.22) 0.92b (0.86–0.97) 0.89c (0.86–0.92)
  no 1.00 reference 1.00 reference 1.00 reference 1.00 reference 1.00 reference
Notes: aahr based on Cox proportional hazards model. Model for each nsCLC histologic subtype adjusted for period of diagnosis, gender, age at diagnosis, ethnicity/race, 
tumor grade at diagnosis, and receipt of cancer-directed surgery and radiation; bP value ,0.05 (two-sided); cP value ,0.001 (two-sided).
Abbreviations: aHR, adjusted hazard ratio; BAC, bronchioloalveolar adenocarcinoma; CI, confidence interval.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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histology, over 94% (representing .27% of the entire sample) 
were carcinomas not otherwise specified (NOS). This is in 
agreement with a recent study of data from the California 
Cancer Registry (1989–2006), demonstrating that carcinoma 
NOS is a common NSCLC histologic diagnosis (especially 
in stage IV disease and among the elderly) and has been 
increasing over time.28 Further, the authors indicated that 
carcinoma NOS patients had the poorest survival among 
the major NSCLC histologies and derived less benefit from 
chemotherapy than patients with adenocarcinoma. Although 
definitive histologic diagnosis can be difficult, it provides 
important data in tailoring treatment, particularly as new 
targeted agents become available.12
The SEER Program provides population-based data 
on cancer incidence and survival in the US and is consid-
ered the gold standard for quality among cancer registries 
  worldwide.29 Nonetheless, our study has important limita-
tions. Tumors included for study did not undergo central 
or independent pathology review. Although this makes 
our findings more generalizable, it introduces heteroge-
neity in disease classification and increases the potential 
for misclassification. However, the accuracy of NSCLC 
histologic reporting in SEER has been assessed favorably 
in comparison with independent histologic review.30 An 
additional limitation of this study is that minor changes 
in lung cancer histological classification (eg, LCNEC was 
previously considered small cell lung cancer and introduced 
as a new subtype of NSCLC under large cell carcinoma in 
199931) during the study period may have slightly influenced 
some of the survival estimates or observed trends. Lastly, 
we were unable to directly evaluate the effects of tobacco 
use, chemotherapy utilization, treatments throughout the 
disease course, performance status, and comorbid conditions 
on survival outcomes, as information on these variables is 
either incomplete or unavailable in SEER.
This large population-based study provides a recent and 
comprehensive description of survival by major histologic 
subtype in stage IV NSCLC in the US. Although we detected 
moderate improvements in survival across the study period, 
more progress is needed. We also found that survival and 
the influence of some important prognostic factors vary 
according to NSCLC histology and that carcinoma NOS 
represents a common histologic diagnosis in stage IV disease. 
Given that data from recent trials of various chemotherapy 
regimens suggest that NSCLC histology may be prognostic 
or predictive of clinical efficacy outcomes, our findings 
highlight the need for continued refinement of NSCLC his-
tologic classifications and definitive tumor subclassification 
at diagnosis to help realize the promise of target-specific 
chemotherapeutics and   ultimately prolong survival in patients 
with advanced NSCLC. More research using other sources 
of population-based data could help clarify the role of his-
tology in the presentation, management, and prognosis of 
late-stage NSCLC.
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